The table of contents on the first page contains quick links to the referenced page numbers in this Chapter. Refer to the notes at the end of a Section to learn about the history of a rule as it was published in the Arizona Administrative Register.

Sections, Parts, Exhibits, Tables or Appendices codified in this supplement. The list provided contains quick links to the updated rules.

R9-4-101. Definitions, General ........................................... 2
R9-4-201. Definitions .......................................................... 2
R9-4-202. Pesticide Illness Reporting Requirements .......... 3
R9-4-301. Definitions .......................................................... 3
R9-4-302. Blood Lead Level Reporting Requirements ....... 3
R9-4-401. Definitions .......................................................... 4
R9-4-402. Exceptions .......................................................... 6
R9-4-403. Case Reports ....................................................... 6
R9-4-404. Requirements for Submitting Case Reports and Follow-up Reports and Allowing Review of Hospital Records .......................................................... 8
R9-4-405. Data Quality Assurance ........................................... 9
R9-4-501. Definitions .......................................................... 10
R9-4-502. Reporting Sources; Information Submitted to the Department .......................................................... 11
R9-4-503. Review of Records; Information Collected .......... 12
R9-4-504. Data Quality Assurance and Follow-up ............ 14

Questions about these rules? Contact:

Name: Georgia Yee, Office Chief
Address: Department of Health Services
Bureau of Public Health Statistics
150 N. 18th Ave., Suite 550
Phoenix, AZ 85007-3248

Telephone: (602) 542-7321
Fax: (602) 364-0296
E-mail: Georgia.Yee@azdhs.gov

or

Name: Eric Thomas, Office Chief
Address: Department of Health Services
Office of Environmental Health
150 N. 18th Ave., Suite 140
Phoenix, AZ 85007-3248

Telephone: (602) 364-3142
Fax: (602) 364-3146
E-mail: Eric.Thomas@azdhs.gov

or

Name: Robert Lane, Office Chief
Address: Department of Health Services
Office of Administrative Counsel and Rules
150 N. 18th Ave., Suite 200
Phoenix, AZ 85007

Telephone: (602) 542-1020
Fax: (602) 364-1150
E-mail: Robert.Lane@azdhs.gov

The release of this Chapter in Supp. 19-4 replaces Supp. 18-2, 1-17 pages
Please note that the Chapter you are about to replace may have rules still in effect after the publication date of this supplement. Therefore, all superseded material should be retained in a separate binder and archived for future reference.
Under Arizona law, the Department of State, Office of the Secretary of State (Office), accepts state agency rule filings and is the publisher of Arizona rules. The Office of the Secretary of State does not interpret or enforce rules in the Administrative Code. Questions about rules should be directed to the state agency responsible for the promulgation of the rule.

Scott Cancelosi, Director
ADMINISTRATIVE RULES DIVISION

RULES
The definition for a rule is provided for under A.R.S. § 41-1001. “Rule” means an agency statement of general applicability that implements, interprets, or prescribes law or policy, or describes the procedures or practice requirements of an agency.”

THE ADMINISTRATIVE CODE
The Arizona Administrative Code is where the official rules of the state of Arizona are published. The Code is the official codification of rules that govern state agencies, boards, and commissions.

The Code is separated by subject into titles. Titles are divided into chapters. A chapter includes state agency rules. Rules in chapters are divided into Articles, then Sections. The “R” stands for “rule” with a sequential numbering and lettering outline separated into subsections.

Rules are codified quarterly in the Code. Supplement release dates are printed on the footers of each chapter.

First Quarter: January 1 - March 31
Second Quarter: April 1 - June 30
Third Quarter: July 1 - September 30
Fourth Quarter: October 1 - December 31
For example, the first supplement for the first quarter of 2019 is cited as Supp. 19-1.

Please note: The Office publishes by chapter, not by individual rule section. Therefore there might be only a few sections codified in each chapter released in a supplement. Historical notes at the end of a section provide an effective date and information when a rule was last updated.

AUTHENTICATION OF PDF CODE CHAPTERS
The Office began to authenticate chapters of the Administrative Code in Supp. 18-1 to comply with A.R.S. § 41-1012(B) and A.R.S. § 5302(1), (2)(d) through (e), and (3)(d) through (e).

A certification verifies the authenticity of each Code chapter posted as it is released by the Office of the Secretary of State. The authenticated pdf of the Code includes an integrity mark with a certificate ID. Users should check the validity of the signature, especially if the pdf has been downloaded. If the digital signature is invalid it means the document’s content has been compromised.

HOW TO USE THE CODE
Rules may be in effect before a supplement is released by the Office. Therefore, the user should refer to issues of the Arizona Administrative Register for recent updates to rule Sections.

ARIZONA REVISED STATUTE REFERENCES
The Arizona Revised Statutes (A.R.S.) are available online at the Legislature’s website, www.azleg.gov. An agency’s authority note to make rules is often included at the beginning of a chapter. Other Arizona statutes may be referenced in rule under the A.R.S. acronym.

SESSION LAW REFERENCES
Arizona Session Law references in a chapter can be found at the Secretary of State’s website, under Services-> Legislative Filings.

EXEMPTIONS FROM THE APA
It is not uncommon for an agency to be exempt from the steps outlined in the rulemaking process as specified in the Arizona Administrative Procedures Act, also known as the APA (Arizona Revised Statutes, Title 41, Chapter 6, Articles 1 through 10). Other agencies may be given an exemption to certain provisions of the Act.

An agency’s exemption is written in law by the Arizona State Legislature or under a referendum or initiative passed into law by Arizona voters.

When an agency files an exempt rulemaking package with our Office it specifies the law exemption in what is called the preamble of rulemaking. The preamble is published in the Register online at www.azsos.gov/rules, click on the Administrative Register link.

Editor’s notes at the beginning of a chapter provide information about rulemaking sections made by exempt rulemaking. Exempt rulemaking notes are also included in the historical note at the end of a rulemaking Section.

The Office makes a distinction to certain exemptions because some rules are made without receiving input from stakeholders or the public. Other exemptions may require an agency to propose exempt rules at a public hearing.

EXEMPTIONS AND PAPER COLOR
At one time the office published exempt rules on either blue or green paper. Blue meant the authority of the exemption was given by the Legislature; green meant the authority was determined by a court order. In 2001 the Office discontinued publishing rules using these paper colors.

PERSONAL USE/COMMERCIAL USE
This chapter is posted as a public courtesy online, and is for private use only. Those who wish to use the contents for resale or profit should contact the Office about Commercial Use fees. For information on commercial use fees review A.R.S. § 39-121.03 and 1 A.A.C. 1, R1-1-113.

Rhonda Paschal, managing rules editor, assisted with the editing of this chapter.
ARTICLE 1. DEFINITIONS
Section
R9-4-101. Definitions, General ............................................. 2
R9-4-102. Repealed ..................................................... 2
R9-4-103. Repealed ..................................................... 2
R9-4-104. Repealed ..................................................... 2
R9-4-105. Repealed ..................................................... 2

ARTICLE 2. PESTICIDE ILLNESS
Section
R9-4-201. Definitions ..................................................... 2
R9-4-202. Pesticide Illness Reporting Requirements ......... 3

ARTICLE 3. BLOOD LEAD LEVELS
Section
R9-4-301. Definitions ..................................................... 3
R9-4-302. Blood Lead Level Reporting Requirements ....... 3
Table 3.1. Criteria for Physician Reporting of Blood Lead Levels ................................................. 4
Table 3.2. Criteria for Clinical Laboratory Director Reporting of Blood Lead Levels ............................ 4

ARTICLE 4. CANCER REGISTRY
Section
R9-4-401. Definitions ..................................................... 4
R9-4-401.01. Repealed ..................................................... 4
R9-4-402. Exceptions ..................................................... 6
R9-4-403. Case Reports ................................................. 6
R9-4-404. Requirements for Submitting Case Reports and Follow-up Reports and Allowing Review of Hospital Records ................................................. 8
R9-4-405. Data Quality Assurance ................................... 9

ARTICLE 5. BIRTH DEFECTS MONITORING PROGRAM
Section
R9-4-501. Definitions ..................................................... 10
R9-4-502. Reporting Sources; Information Submitted to the Department ................................................. 11
R9-4-503. Review of Records; Information Collected ........ 12
R9-4-504. Data Quality Assurance and Follow-up .......... 14

ARTICLE 6. OPIOID POISONING-RELATED REPORTING
Emergency expired; new Article 6, consisting of Sections R9-4-601 and R9-4-602 amended by emergency rulemaking at 24 A.A.R. 630, effective March 20, 2018, for 180 days (Supp. 18-1).

New Article 6, consisting of Sections R9-4-601 and R9-4-602 made by emergency rulemaking at 23 A.A.R. 2857, effective September 21, 2017, for 180 days (Supp. 17-3).

Section
R9-4-601. Definitions ..................................................... 14
R9-4-602. Opioid Poisoning-Related Reporting Requirements ................................................. 15
CHAPTER 4. DEPARTMENT OF HEALTH SERVICES - NONCOMMUNICABLE DISEASES

ARTICLE 1. DEFINITIONS

R9-4-101. Definitions, General
In this Chapter, unless otherwise specified:

2. “Business day” means any day of the week other than a Saturday, a Sunday, a state legal holiday, or a day on which the Department is authorized or obligated by law or executive order to close.
3. “Calendar day” means any day of the week, including a Saturday or a Sunday.
4. “Clinical laboratory” means a facility that:
   a. Meets the definition in A.R.S. § 36-451;
   b. Holds a certificate of accreditation or certificate of compliance issued by the United States Department of Health and Human Services under the 1988 amendments to the Clinical Laboratories Improvement Act of 1967; and
   c. Is located within Arizona.
5. “Code” means a single number or letter, a set of numbers or letters, or a set of both numbers and letters that represents specific information.
6. “Dentist” means an individual licensed under A.R.S. Title 32, Chapter 11, Article 2.
8. “Diagnosis” means the identification of a disease or injury, by an individual authorized by law to make the identification.
10. “Discharge date” means the month, day, and year of an individual’s discharge from a hospital.
12. “Guardian” means a person appointed as a legal guardian by a court of competent jurisdiction.
14. “Health-related services” means the same as in A.R.S. § 36-401.
15. “Hospital” means the same as in A.A.C. R9-10-101.
16. “International Classification of Diseases Code” or “ICD Code” means a code, such as the ICD-9-CM or ICD-10-CM codes, which is used by a hospital for billing or reporting purposes.
17. “Medical records” means the same as in A.R.S. § 12-2291.
18. “Medical services” means the same as in A.R.S. § 36-401.
19. “Nursing services” means the same as in A.R.S. § 36-401.
20. “Ordered” means instructed by a physician, registered nurse practitioner, or physician assistant to perform a test on an individual.
21. “Parent” means the:
   a. Biological or adoptive father of an individual; or
   b. Woman who:
      i. Gave birth to an individual; or
      ii. Adopts an individual.
22. “Pathology laboratory” means a clinical laboratory in which human cells or tissues are examined for the purpose of diagnosing diseases.
23. “Physician” means an individual licensed as a doctor of allopathic medicine under A.R.S. Title 32, Chapter 13, or as a doctor of osteopathic medicine under A.R.S. Title 32, Chapter 17.
24. “Physician assistant” has the same meaning as in A.R.S. § 32-2501.
25. “Registered nurse practitioner” means an individual who meets the definition of registered nurse practitioner in A.R.S. § 32-1001, and is licensed under A.R.S. Title 32, Chapter 15.
to be caused by or related to documented exposure to any pesticide, based upon professional judgment and:

(a) the history, signs, or symptoms of the sickness;
(b) laboratory findings indicating the individual;
(c) the individual’s response to treatment for the sickness.

7. “Poison control center” means an organization that is a member of and may be certified by the American Association of Poison Control Centers.

Historical Note

R9-4-202. Pesticide Illness Reporting Requirements

A. A health care professional or medical director who believes that an individual has pesticide illness shall submit a report to the Department, either personally or through a representative:

1. Except as specified in subsections (A)(2) and (C), within five business days after the health care professional determines that the individual may have pesticide illness; and
2. Within one business day after the individual is admitted to a hospital or dies due to pesticide illness.

B. Except as specified in subsection (C), a medical director who believes that an individual has pesticide illness shall submit a report to the Department, either personally or through a representative at least once each month.

C. A health care professional or medical director who believes that an individual is part of a cluster illness shall submit a report to the Department, either personally or through a representative, within one business day after determining that the individual has pesticide illness.

D. A health care professional or medical director shall ensure that the report required in subsection (A), (B), or (C) includes the following information:

1. The name, address, and telephone number of the individual with pesticide illness;
2. The date of birth of the individual with pesticide illness;
3. The gender, race, and ethnicity of the individual with pesticide illness;
4. The date symptoms of pesticide illness began;
5. The date the health care professional or medical director determined that the individual may have pesticide illness;
6. The occupation of the individual with pesticide illness;
7. The name of the pesticide, if known;
8. The symptoms reported by the individual with pesticide illness;
9. Whether any laboratory tests were performed for the individual with pesticide illness and, if so, for each test:
   a. The type of specimen collected;
   b. The date the specimen was collected;
   c. The type of test performed;
   d. The results of the test, and
   e. What results of the test would be considered normal;
10. A description of any treatment provided to the individual with pesticide illness;
11. On what basis the health care professional or medical director believes the individual has pesticide illness;
12. The name and telephone number of the health care professional or medical director who believes that the individual has pesticide illness;
13. The name and address of the health care institution or poison control center at which the health care professional or medical director determined that the individual may have pesticide illness; and
14. A description of the type of health care institution or poison control center specified in subsection (D)(13).

E. A health care professional or medical director, either personally or through a representative, shall submit the report required in subsection (A), (B), or (C):

1. By telephone;
2. In person;
3. In a document sent by fax, delivery service, or mail; or
4. Through an electronic reporting system authorized by the Department.

Historical Note
New Section renumbered from R9-4-201 and amended by final rulemaking at 6 A.A.R. 2948, effective July 18, 2000 (Supp. 00-3). Amended by final rulemaking at 25 A.A.R. 3429, effective January 1, 2020 (Supp. 19-4).

ARTICLE 3. BLOOD LEAD LEVELS

R9-4-301. Definitions
In this Article, unless otherwise specified:

1. “Adult” means an individual 16 years of age or older.
2. “Child” means an individual younger than 16 years of age.
3. “Patient” means the individual whose blood has been
4. “Point-of-care test for blood lead” means an analysis to screen an individual for exposure to lead:
   a. That is performed outside a clinical laboratory, and
   b. For which the results of the analysis are available before the individual leaves the location at which the analysis was performed.
5. “Whole blood” means human blood from which plasma, erythrocytes, leukocytes, and thrombocytes have not been separated.

Historical Note

R9-4-302. Blood Lead Level Reporting Requirements

A. For each patient, a physician shall submit a report to the Department, either personally or through a representative, for the levels of lead and within the time periods specified in Table 3.1, Criteria for Physician Reporting of Blood Lead Levels.

B. A physician shall ensure that the report required in subsection (A) includes the following information:

1. The patient’s name, address, and telephone number;
2. The patient’s date of birth;
3. The patient’s gender, race, and ethnicity;
4. If the patient is an adult, the patient’s occupation and the patient’s employer;
5. Whether the blood collected from the patient was venous blood or capillary blood;
6. The date the blood was collected;
7. The results of the blood lead level test;
8. The date of the test result;
9. If the test result indicates a blood lead level greater than or equal to 25 µg of lead per dL of whole blood for an
For each blood lead level test, a clinical laboratory director shall ensure that the report required in subsection (A) or (C) includes the following information:

1. The patient’s name, address, and telephone number;
2. The patient’s date of birth;
3. The patient’s gender, race, and ethnicity;
4. If the patient is an adult, the patient’s occupation and the name, address, and telephone number of the patient’s employer if known;
5. The name, practice name, address, and telephone number of the physician who ordered the test;
6. If known, the funding source for the test for blood lead, the name of the patient’s health plan, and the identification number for the patient assigned by the health plan;
7. Whether the blood collected from the patient was venous blood or capillary blood;
8. The date the blood was collected;
9. The results of the blood lead level test;
10. The date of the test result;
11. The name and address of the clinical laboratory that tested the blood; and
12. The name and telephone number of the clinical laboratory director.

A physician or clinical laboratory director, either personally or through a representative, shall submit the report required in subsection (C) includes the following information:

1. By telephone;
2. In person;
3. In a document sent by fax, delivery service, or mail; or
4. Through an electronic reporting system authorized by the Department.

<table>
<thead>
<tr>
<th>Table 3.1. Criteria for Physician Reporting of Blood Lead Levels</th>
<th>Child</th>
<th>Adult</th>
</tr>
</thead>
<tbody>
<tr>
<td>Within One Business Day After Performing a Point-of-Care Test for Blood Lead or Receiving the Result of a Test for Blood Lead from a Clinical Laboratory</td>
<td>≥ 45 µg of lead per dL of whole blood</td>
<td>≥ 60 µg of lead per dL of whole blood</td>
</tr>
<tr>
<td>Within Five Business Days After Performing a Point-of-Care Test for Blood Lead or Receiving the Result of a Test for Blood Lead from a Clinical Laboratory</td>
<td>≥ 10 µg to &lt; 45 µg of lead per dL of whole blood</td>
<td>≥ 25 µg to &lt; 60 µg of lead per dL of whole blood</td>
</tr>
<tr>
<td>At Least Once Each Month After Performing a Point-of-Care Test for Blood Lead</td>
<td>&lt; 10 µg of lead per dL of whole blood</td>
<td>&lt; 25 µg of lead per dL of whole blood</td>
</tr>
</tbody>
</table>

**Historical Note**
Table 3.1 made by final rulemaking at 25 A.A.R. 3429, effective January 1, 2020 (Supp. 19-4).

<table>
<thead>
<tr>
<th>Table 3.2. Criteria for Clinical Laboratory Director Reporting of Blood Lead Levels</th>
<th>Child</th>
<th>Adult</th>
</tr>
</thead>
<tbody>
<tr>
<td>Within One Business Day After Completing the Test</td>
<td>≥ 45 µg of lead per dL of whole blood</td>
<td>≥ 60 µg of lead per dL of whole blood</td>
</tr>
<tr>
<td>Within Five Business Days After Completing the Test</td>
<td>≥ 10 µg to &lt; 45 µg of lead per dL of whole blood</td>
<td>≥ 25 µg to &lt; 60 µg of lead per dL of whole blood</td>
</tr>
<tr>
<td>At Least Once Each Month</td>
<td>&lt; 10 µg of lead per dL of whole blood</td>
<td>&lt; 25 µg of lead per dL of whole blood</td>
</tr>
</tbody>
</table>

**Historical Note**
Table 3.2 made by final rulemaking at 25 A.A.R. 3429, effective January 1, 2020 (Supp. 19-4).

**ARTICLE 4. CANCER REGISTRY**

**R9-4-401. Definitions**

In this Article, unless otherwise specified:

1. “Analytic patient” means a patient, who is:
   a. Diagnosed at a facility, or
   b. Administered any part of a first course of treatment at the facility.

2. “Calendar year” means January 1 through December 31.

3. “Cancer” means a group of diseases characterized by uncontrolled cell growth and the spread of abnormal cells.

4. “Cancer registry” means a unit within a hospital or clinic that collects, stores, summarizes, distributes, and maintains information specified in R9-4-403 about patients who:
a. Are admitted to the hospital;
b. Receive diagnostic evaluation at, or cancer-directed treatment from, the hospital or clinic;
c. Show evidence of cancer, carcinoma in situ, or a benign tumor of the central nervous system while receiving treatment from the hospital or clinic.

5. “Carcinoma” means a type of cancer that is characterized as a malignant tumor derived from epithelial tissue.

6. “Carcinoma in situ” means a cancer that is confined to epithelial tissue within the site of origin.

7. “Case report” means an electronic or paper document that includes the information in R9-4-403 for a patient.

8. “Chemotherapy” means the treatment of cancer using specific chemical agents or drugs that are selectively destructive to malignant cells and tissues.

9. “Clinic” means a facility that is not physically connected to or affiliated with a hospital, where a physician, doctor of naturopathic medicine, dentist, or registered nurse practitioner provides cancer diagnosis, cancer treatment, or both, and that is:
   a. An outpatient treatment center, as defined in A.A.C.
   b. An outpatient surgical center, as defined in A.A.C.
   c. An outpatient radiation treatment center;
   d. A private office of one or more physicians, doctors of naturopathic medicine, dentists, or registered nurse practitioners that:
      i. Is exempt from licensing under A.R.S. § 36-402(A)(3), and
      ii. Treats 50 or more cancer patients per year.

10. “Clinical evaluation” means an examination of the body of an individual for the presence of disease or injury to the body, and review of any laboratory test results for the individual by a physician, doctor of naturopathic medicine, dentist, or registered nurse practitioner provides cancer diagnosis, cancer treatment, or both.

11. “Clinical or pathological” means an analysis of evidence either acquired solely before a first course of treatment was initiated, or acquired both before a first course of treatment, and supplemented or modified by evidence acquired during and subsequent to surgery or other treatment.

12. “Cytology” means the microscopic examination of cells.

13. “Date of first contact” means the day, month, and year a reporting facility first began to provide cancer-related medical services, nursing services, or health-related services, as defined in A.R.S. § 36-401, to a patient.

14. “Date of last contact” means the day, month, and year that a reporting facility last knew a patient to be alive.

15. “Designee” means a person assigned by the governing authority, as defined in A.R.S. § 36-401, of a hospital or clinic or by an individual acting on behalf of the governing authority to gather information for or report to the Department, as specified in R9-4-403 or R9-4-404.

16. “Distant lymph node” means a lymph node that is not in the same general area of a human body as the primary site of a tumor.

17. “Distant site” means an area of a human body that is not adjacent to or in the same general area of the human body as the primary site of a tumor.


19. “First course of treatment” means the initial set of cancer- or non-cancer-directed treatment that is planned and administered to the patient when a cancer is diagnosed.

20. “Follow-up report” means an electronic document that includes the information stated in R9-4-404(A)(2) for a patient.


22. “Licensed capacity” means the same as in A.R.S. § 36-401.

23. “Lymph” means the clear, watery, sometimes faintly yellowish fluid that circulates throughout the lymphatic system.

24. “Lymph node” means any of the small bodies located along lymphatic vessels, particularly at the neck, armpit, and groin, that filter bacteria and foreign particles from lymph.

25. “Lymphatic system” means the organ system that consists of lymph, lymph nodes, and vessels or channels that contain and convey lymph throughout a human body.

26. “Malignant” means an inherent tendency of a tumor to sequentially spread to areas of a human body beyond the site of origin.

27. “Medical record number” means a unique number assigned by a hospital, clinic, physician, doctor of naturopathic medicine, dentist, or registered nurse practitioner to an individual for identification purposes.

28. “Melanocyte” means a skin cell that makes melanin, which is a dark pigment.

29. “Melanoma” means a dark-pigmented, malignant tumor arising from a melanocyte and occurring most commonly in the skin.

30. “Metastasis” means the spread of a cancer from a primary site into a regional site or a distant site.

31. “Narrative description” means a written text describing an act, occurrence, or course of events.

32. “Organ” means a somewhat independent part of a human body, such as a heart or a kidney, that performs a specific function.

33. “Organ system” means one or more organs and associated tissues that perform a specific function, such as the circulatory system.

34. “Outpatient radiation treatment center” means a facility regulated under 9 A.A.C. 7 that provides radiation treatment.

35. “Patient” means an individual who has been diagnosed with a cancer, carcinoma in situ, or benign tumor of the central nervous system:
   a. Including melanoma; and
   b. Excluding skin cancer that:
      i. Is confined to the primary site, or

36. “Primary site” means a specific organ or organ system within a human body where the first cancer tumor originated.

37. “Principal diagnosis” means the primary condition for which an individual is admitted to a hospital or treated by the hospital.

38. “Radiation treatment” means the exposure of a human body to a stream of particles or electromagnetic waves for the purpose of selectively destroying certain cells or tissues.

39. “Reconstructive surgery” means a medical procedure that involves cutting into a body tissue or organ with instruments to repair damage or restore function to, or improve the shape and appearance of, a body structure that is missing, defective, damaged, or misshapen by cancer or cancer-directed therapies.

40. “Reference date” means the date on which the hospital’s cancer registry began reporting patient information to the Department.
41. “Regional lymph node” means a lymph node that is in the same general area of a human body as the primary site of a tumor.
42. “Regional site” means an area of a human body that is adjacent to or in the same general area of the human body as the primary site of a tumor.
43. “Release” means to transfer care of a patient from a hospital to a physician, a doctor of naturopathic medicine, a registered nurse practitioner, an outpatient treatment center, another hospital, the patient, the patient’s parent if the patient is under 18 years of age and unmarried, or the patient’s legal guardian.
44. “Reporting facility” means a hospital, clinic, physician, doctor of naturopathic medicine, dentist, or registered nurse practitioner that submits a case report to the Department.
45. “Secondary diagnosis” means all other diagnoses of an individual that may be related to cancer made after the principal diagnosis.
46. “Skin cancer” means cancer of any of the following types:
   a. Papillary tumor, a tumor of the skin producing finger-like projections from the skin surface;
   b. Squamous cell, a flat, scale-like skin cell that forms part of the surface of the skin;
   c. Basal cell, a cell of the inner-most layer of the skin;
   d. Other carcinoma of the skin, where a specific diagnosis has not been determined.
47. “Stage group” means a scheme for categorizing a patient, based on the staging classification of the patient’s cancer, to enable a physician, doctor of naturopathic medicine, or registered nurse practitioner to provide better treatment and outcome information to the patient.
48. “Staging classification” means the categorization of a cancer according to the size and spread of a tumor from its primary site, based on an analysis of three basic components:
   a. The tumor at the primary site,
   b. Regional lymph nodes, and
   c. Metastasis.
49. “Tumor” means an abnormal growth of tissue resulting from uncontrolled multiplication of cells and serving no physiological function.

**Historical Note**

**R9-4-401. Repealed**

**Historical Note**
New Section made by final rulemaking at 9 A.A.R. 1859, effective June 3, 2003 (Supp. 03-2). Section repealed by final rulemaking at 12 A.A.R. 179, effective March 11, 2006 (Supp. 06-1).

**R9-4-402. Exceptions**
This Article does not apply to a hospital that is a special hospital, as defined in A.A.C. R9-10-101, that:
1. Is only licensed to provide psychiatric services, or
2. Limits admission to individuals requiring rehabilitation services, as defined in A.A.C. R9-10-101.
The cancer registry of a hospital that reports as specified in subsection (A)(2) shall:

1. Prepare a case report in a format provided by the Department.
2. Include the information specified in subsection (A) and the following information in the case report:
   a. The patient’s unique accession number, separate from a medical record number, that was assigned by the hospital’s cancer registry to the patient for identification purposes;
   b. The unique sequence number assigned by the cancer registry to the specific cancer within the body of the patient being reported;
   c. The date the patient was admitted to the hospital for diagnostic evaluation, cancer-directed treatment, or evidence of cancer, carcinoma in situ, or a benign tumor of the central nervous system, if applicable;
   d. The date the patient was discharged from the hospital after the patient received diagnostic evaluation or treatment at the hospital, if applicable;
   e. The source of payment for diagnosis or treatment of cancer, or both;
   f. The level of the facility’s involvement in the diagnosis or treatment, or both, of the patient for cancer;
   g. The year in which the hospital first provided diagnosis or treatment to the patient for the cancer being reported;
   h. The patient’s county of residence at diagnosis of cancer;
   i. The patient’s marital status and age at diagnosis of cancer, place of birth, and, if applicable, name of the patient’s spouse;
   j. If the patient is under 18 years of age and unmarried, the name of the patient’s parent or legal guardian;
   k. A narrative description of how the cancer was diagnosed, including a description of the primary site and the microscopic structure of the tumor cells and surrounding tissues;
   l. The number of regional lymph nodes examined and the number in which evidence of cancer was detected;
   m. The clinical, pathological, or other staging classification, based on the analysis of tumor, lymph node, and metastasis;
   n. The patient’s clinical, pathological, or other stage group;
   o. If the cancer was diagnosed before 2018, the code for the person who determined the stage group of the patient;
   p. A narrative description of the clinical evaluation of x-ray diagnostic films and scans of the patient, and the dates of the films or scans;
   q. A narrative description of laboratory tests performed for the patient, including the date, type, and results of any of the patient’s laboratory tests;
   r. A narrative description of the results of the patient’s clinical evaluation;
   s. The procedures used by the reporting facility to obtain a diagnosis and staging classification, including:
      i. The dates on which the procedures were performed; and
      ii. The name of the facilities where the procedures were performed, if different from the reporting facility;
   t. A narrative description of any cancer-related surgery on the patient, including the:
      i. Date of surgery;
      ii. Name of the facility where the surgery was performed, if different from the reporting facility; and
      iii. Type of surgery;
   u. The code associated with the type of surgery performed on the patient and the date of surgery;
   v. The codes associated with the:
      i. Extent of lymph node surgery;
      ii. Number of lymph nodes removed;
      iii. Surgery of regional sites, distant sites, or distant lymph nodes; and
      iv. Reason for no surgery or that surgery was performed;
   w. Whether reconstructive surgery on the patient was performed as a first course of treatment, delayed, or not performed;
   x. A narrative description of cancer-related radiation treatment administered to the patient, including the:
      i. Date of radiation treatment;
      ii. Name of the facility where the radiation treatment was performed, if different from the reporting facility; and
      iii. Type of radiation;
   y. As applicable, the code specifying that radiation treatment was administered or associated with the reason for no radiation treatment;
   z. The code associated with the type of radiation treatment administered to the patient and the date of radiation treatment;
   aa. A narrative description of cancer-related chemotherapy administered to the patient, including the:
      i. Date of cancer-related chemotherapy;
      ii. Name of the facility that administered the chemotherapy, if different from the reporting facility; and
      iii. Type of chemotherapy;
Requirements for Submitting Case Reports and Follow-up Reports and Allowing Review of Hospital Records

A. The cancer registry of a hospital with a licensed capacity of 50 or more inpatient beds shall ensure that:

1. An electronic case report, prepared according to R9-4-403(B), is submitted to the Department within 180 calendar days after the date a patient is first released from the hospital.

2. An electronic follow-up report, for correcting information previously submitted according to R9-4-403(A)(2)(j) through (l), or (B)(2)(a), (b), (m), (n), or (w), is submitted to the Department:
   a. Within 30 calendar days after identifying the correct information and at least annually,
   b. For all patients for whom applicable corrected information is obtained,
   c. That includes patient identifying information and the information to be corrected, and
   d. In a format provided by the Department; and

3. An electronic follow-up report for analytic patients, in a format provided by the Department:
   a. Is submitted to the Department at least annually for:
      i. All living analytic patients in the hospital’s cancer registry database, and
      ii. All analytic patients in the hospital’s cancer registry database who have died since the last follow-up report; and
   b. Includes, as applicable:
      i. A change of patient address;
      ii. A summary of additional first course of treatment;
      iii. The information in R9-4-403(A)(2)(s), (u), (v), and (w) and R9-4-403(B)(2)(gg).

B. The cancer registry or other designee of a hospital with a licensed capacity of fewer than 50 inpatient beds shall either report as specified in subsection (A), or shall at least once every six months:

1. Prepare and submit to the Department, in a format provided by the Department:
   a. For all individuals:
      i. Released by the hospital since the last report was prepared, and
      ii. Whose medical records include ICD Codes specified in a list provided to the hospital by the Department; and
   b. The following information for each individual:
      i. The individual’s medical record number assigned by the hospital,
      ii. The individual’s date of birth,
      iii. The individual’s admission and discharge dates,
      iv. All applicable ICD Codes for the individual that are in the list in subsection (B)(1)(a)(ii), and
      v. Whether the ICD Code reflects the individual’s principal or secondary diagnosis; and

2. Allow the Department to review the records listed in R9-4-405(A) to obtain the information specified in R9-4-403 about a patient.

C. If the designee of a clinic submitted 100 or more case reports to the Department in the previous calendar year or expects to submit 100 or more case reports in the current calendar year, the designee of the clinic shall:

1. Submit to the Department a case report, prepared according to R9-4-403(A), for each patient who is not referred by the clinic to a hospital for the first course of treatment; and

2. Ensure that the case report in subsection (C)(1) is submitted in electronic format within 90 calendar days after:
   a. Initiation of treatment of the patient at the clinic; or
CHAPTER 4. DEPARTMENT OF HEALTH SERVICES - NONCOMMUNICABLE DISEASES

R9-4-405. Data Quality Assurance

A. To ensure completeness and accuracy of cancer reporting:

1. Upon notice from the Department of at least five business days, a hospital, clinic, physician, doctor of naturopathic medicine, dentist, or registered nurse practitioner required to report under R9-4-404 shall allow the Department to review any of the following records, as are applicable to the facility:
   a. A report meeting the requirements of R9-4-404(B)(1);
   b. Patient medical records;
   c. Medical records of individuals not diagnosed with cancer;
   d. Pathology reports;
   e. Cytology reports;
   f. Logs containing information about surgical procedures, as specified in A.A.C. R9-10-215(6) or A.A.C. R9-10-911(A);
   g. Records other than those specified in subsections (A)(1)(a) through (f) that contain information about diagnostic evaluation, cancer-directed treatment, or other treatment provided to an individual by the hospital, clinic, physician, doctor of naturopathic medicine, dentist, or registered nurse practitioner;

2. Within 14 calendar days after the Department’s request, a hospital, clinic, physician, doctor of naturopathic medicine, dentist, or registered nurse practitioner required to report under R9-4-404 shall submit the following information about patients who were diagnosed with cancer or received treatment for cancer within the time period specified in the Department’s request whose medical records include ICD Codes specified in a list provided by the Department:
   a. The individual’s name and date of birth;
   b. The individual’s medical record number;
   c. The individual’s admission and discharge dates;
   d. All applicable codes for the individual that are in the list provided by the Department, and
   e. Whether the code reflects the individual’s principal or secondary diagnosis; and

3. Within 14 calendar days after the Department’s request, a hospital shall resubmit all of the information required in R9-4-403(B)(2) for patients first released from the hospital within the time period specified in the Department’s request.

B. The Department shall consider a hospital, clinic, physician, doctor of naturopathic medicine, dentist, or registered nurse practitioner required to report under R9-4-404 as meeting the criteria in R9-4-404 if the hospital, clinic, physician, doctor of naturopathic medicine, dentist, or registered nurse practitioner submits a case report to the Department for at least 97% of the patients for whom a case report is required under R9-4-404 during a calendar year.

C. The Department shall consider a hospital required to report under R9-4-404(A)(3) as meeting the criteria in R9-4-404(A)(3) if the hospital submits a follow-up report specified in R9-4-404(A)(3) to the Department once each calendar year for at least:

1. Eighty percent of all analytic patients from the hospital’s reference date; and
2. Ninety percent of all analytic patients diagnosed within the last five years or from the hospital's reference date, whichever is shorter.

D. The Department shall return a case report not prepared according to R9-4-403 to the hospital, clinic, physician, doctor of naturopathic medicine, dentist, or registered nurse practitioner that submitted the case report, identifying the revisions that are needed in the case report.

E. Upon receiving a case report returned under subsection (D), a hospital, clinic, physician, doctor of naturopathic medicine, dentist, or registered nurse practitioner shall submit the revised case report to the Department within 15 business days after the date the Department requests the revision.

F. Upon written request by the Department, a hospital shall:
   1. Prepare a case report based on a simulated medical record provided by the Department for the purpose of demonstrating the variability with which data is reported, and
   2. Submit the case report to the Department within 15 business days after the date of the request.

Historical Note

ARTICLE 5. BIRTH DEFECTS MONITORING PROGRAM

R9-4-501. Definitions
In this Article, unless otherwise specified:

1. “Birth defect” means an abnormality:
   a. Of body structure, function, or chemistry, or of chromosomal structure or composition;
   b. That is present at or before birth; and
   c. That may be diagnosed before or at birth, or later in life.

2. “Clinic” means:
   a. A person under contract or subcontract with the Arizona Health Care Cost Containment System to provide the services specified in 9 A.A.C. 22, Article 13;
   b. An outpatient treatment center, as defined in A.A.C. R9-10-101;
   c. An outpatient surgical center, as defined in A.A.C. R9-10-101; or
   d. A birth center, as defined in A.A.C. R9-13-201.

3. “Clinical evaluation” means an examination of the body of an individual and review of the individual’s laboratory test results to determine the presence or absence of a medical condition that may be related to a birth defect.

4. “Conception” means the formation of an entity by the union of a human sperm and ovum, resulting in gestation.

5. “Co-twin” means a sibling of a patient, who was born to the same mother as the patient and as a result of the same pregnancy as the patient.

6. “Date of first contact” means the day, month, and year a physician, clinic, or other person specified in R9-4-503(A) first began to provide medical services, nursing services, or health-related services to a patient or the patient’s mother.

7. “Date of last contact” means the day, month, and year:
   a. Of a patient’s death; or
   b. That a physician, clinic, or other person specified in R9-4-503(A) last clinically evaluated, diagnosed, or provided treatment to a patient or the patient’s mother.
CHAPTER 4. DEPARTMENT OF HEALTH SERVICES - NONCOMMUNICABLE DISEASES

ii. By an individual or facility specified in subsection (2)(a);

23. “Perinatal risk factor” means a situation or circumstance that may increase the chance of an individual being born with a birth defect, such as:
   a. A family medical history of birth defects or other medical conditions;
   b. The exposure of the individual or the individual’s mother or biological father to radiation, medicines, chemicals, or diseases before the individual’s birth; or
   c. An abnormal result of a test performed for the individual or the individual’s mother or biological father to radiation, medicines, chemicals, or diseases before the individual’s birth; or

24. “Prenatal diagnostic facility” means an organization, institution, corporation, partnership, business, or entity that conducts diagnostic ultrasound or other medical procedures that may diagnose a birth defect in a human being.

25. “Principal diagnosis” means the primary reason for which an individual is:
   a. Admitted to a hospital;
   b. Treated by a hospital, clinic, midwife, physician, registered nurse practitioner, or physician assistant; or
   c. Tested by a genetic testing facility or prenatal diagnostic facility.

26. “Procedure” means a set of activities performed on a patient or the mother of a patient that:
   a. Are invasive;
   b. Are intended to diagnose or treat a disease, illness, or injury;
   c. Involve a risk to the patient or patient’s mother from the activities themselves or from anesthesia; and
   d. Require the individual performing the set of activities to be trained in the set of activities.

27. “Refer” means to provide direction to an individual or the individual’s parent or guardian to obtain medical services or a test for assessment, diagnosis, or treatment of a birth defect or other medical condition.

28. “Routine” means occurring in the regular or customary course of business.

29. “Secondary diagnosis” means all other diagnoses that may be related to a birth defect for an individual besides the principal diagnosis.

30. “Singleton gestation” means a pregnancy in which a patient is the only fetus carried in a mother’s womb.

31. “Support services” means activities, not related to the diagnosis or treatment of a birth defect, intended to maintain or improve the physical, mental, or psychosocial capabilities of a patient or those individuals biologically or legally related to the patient.

32. “Surgical procedure” means making an incision into an individual’s body for the:
   a. Correction of a deformity or defect,
   b. Repair of an injury,
   c. Excision of a part of the individual’s body, or
   d. Diagnosis, amelioration, or cure of a disease.

33. “Test” means:
   a. An analysis performed on body fluid, tissue, or excretion by a genetic testing facility or other clinical laboratory to evaluate for the presence or absence of a disease; or
   b. A procedure performed on the body of a patient or the patient’s mother that may be used to evaluate for the presence or absence of a birth defect.

34. “Transfer” means for a hospital to discharge a patient or the patient’s mother and send the patient or the patient’s mother to another hospital for inpatient medical services without the intent that the patient or the patient’s mother will return to the sending hospital.


36. “Unit” means an area of a hospital designated to provide an organized service, as defined in A.A.C. R9-10-201.

Historical Note
Adopted effective September 25, 1991 (Supp. 91-3).
Former Section R9-4-501 remodeled to R9-4-502; new Section R9-4-501 adopted by final rulemaking at 7 A.A.R. 712, effective January 17, 2001 (Supp. 01-1).

R9-4-502. Reporting Sources; Information Submitted to the Department
A. The designee of a hospital shall:
   1. Upon the request of the Department and no more often than once per month, prepare a report, in a format specified by the Department, identifying all individuals:
      a. Who are patients or the mothers of patients; and
      b. Whose:
         i. Discharge date is within the time period for which the report is being prepared, as specified in subsection (A)(2)(d); and
         ii. Medical records include for the principal diagnosis, a secondary diagnosis, or a procedure performed on the individual, an ICD Code for a diagnosis or a procedure code specified in a list provided to the hospital by the Department;
   2. Include the following information in the report specified in subsection (A)(1):
      a. The name, address, and telephone number of the hospital, or the identification number assigned by the Department to the hospital;
      b. The name, telephone number, and e-mail address of the designee of the hospital;
      c. The date the report was completed;
      d. The time period for which the report is being prepared; and
      e. For each patient or the mother of the patient:
         i. The patient’s or mother’s medical record number;
CHAPTER 4. DEPARTMENT OF HEALTH SERVICES - NONCOMMUNICABLE DISEASES

A. Upon notice from the Department of at least five business days, the following persons or facilities shall allow the Department access to the facility and the electronic or written records specified in subsection (B)(1) to collect the information specified in subsection (B)(2):

1. A hospital,
2. A clinic,
3. A physician,
4. A midwife,
5. A registered nurse practitioner,
6. A genetic testing facility,
7. A prenatal diagnostic facility,
8. A physician assistant, or
9. A clinical laboratory,

B. The designee of a prenatal diagnostic facility, high-risk perinatal practice, or clinic shall:

1. Upon request of the Department and no more often than once per month, prepare a report, in a format specified by the Department, identifying all individuals:
   a. For whom a specified test was conducted, with test results indicating a diagnosis in a list provided by the Department; or
   b. Whose medical records include a principal diagnosis or secondary diagnosis specified in a list provided by the Department;
2. Include the following information in the report specified in subsection (B)(1):
   a. The type of test performed on the patient or the patient’s mother, and
   b. The date of the test.
   c. The estimated gestational age of the patient when the test was performed, if known;
   d. The location and date of the patient’s birth, if known;
   e. The mother’s name, date of birth, and medical record number;
   f. The estimated gestational age of the patient at the time of the test or diagnosis, as applicable;
   g. The mother’s estimated date of confinement;
   h. The outcome of the pregnancy, if known;
   i. The principal diagnosis and secondary diagnoses for the patient or the patient’s mother;
   j. The patient’s gender, if known;
   k. The location and date of the patient’s birth, if known;
   l. The mother’s name, address, and telephone number of the prenatal diagnostic facility, high-risk perinatal practice, or clinic;
3. Submit the report specified in subsection (A)(1) to the Department, in a format specified by the Department, within 30 calendar days after the Department’s request.

C. The designee of a genetic testing facility shall:

1. Prepare a report, in a format specified by the Department, for all individuals:
   a. Who are patients or the mothers of patients, and
   b. For whom the genetic testing facility performed a test specified in a list provided by the Department;
2. Include the following information in the report specified in subsection (C)(1):
   a. The name, address, and telephone number of the genetic testing facility, or the identification number assigned by the Department to the genetic testing facility;
   b. The name, telephone number, and e-mail address of the designee of the genetic testing facility;
   c. The date the report was completed;
   d. The month for which the report is being prepared, if reporting according to subsection (C)(3)(a); and
   e. For each patient or mother of a patient:
      i. If the test was performed on the patient:
         1. The patient’s name, date of birth, and gender;
         2. The name of the patient’s parent or guardian;
      ii. If the test was performed on the mother of the patient:
         1. The mother’s name and date of birth;
         2. The estimated gestational age of the patient when the test was performed, if available; and
         3. The mother’s estimated date of confinement when the test was performed, if available;
      iii. The name of the physician, registered nurse practitioner, or physician assistant who ordered the test for the patient or the patient’s mother, and
      iv. Information about the test, including:
         1. The type of test performed on the patient or the patient’s mother,
         2. The date the test was completed, and
         3. The results of the test; and
3. Submit to the Department the report specified in subsection (C)(1) and a copy of the test results within 30 calendar days after either:
   a. The end of the month during which the test was completed, or
   b. The date of the test.

Historical Note
10. A medical examiner.

B. The Department may:

1. Review any of the following records in electronic or written format, as are applicable to the person or facility specified in subsection (A):
   a. Patient medical records;
   b. Medical records for the mother of a patient;
   c. Reports from:
      i. Physicians or other individuals who clinically evaluated, diagnosed, or treated a patient or the patient’s mother, including physical therapists, as defined in A.R.S. § 32-2001; occupational therapists, as defined in A.R.S. § 32-3401; podiatrists, as defined in A.R.S. § 32-801; and speech-language pathologists, licensed according A.R.S. Title 35, Chapter 17;
      ii. High-risk perinatal practices;
      iii. Prenatal diagnostic facilities;
      iv. Genetic testing facilities;
      v. Pathology laboratories; or
      vi. Other facilities or clinical laboratories that performed a test for a patient or the patient’s mother;
   d. Logs and registers containing information about surgical procedures, as specified in A.A.C. R9-10-215(6) or A.A.C. R9-10-911(A);
   e. Other logs that may contain information about a patient or the mother of a patient with a birth defect, such as:
      i. Labor and delivery unit logs,
      ii. Nursery unit logs,
      iii. Pediatric unit logs,
      iv. Intensive care unit logs,
      v. Autopsy logs, and
      vi. Ultrasound logs;
   f. Autopsy reports; and
   g. Records other than those specified in subsections (B)(1)(a) through (f) that contain information about or may lead to information about:
      i. A patient,
      ii. The patient’s mother, or
      iii. The patient’s biological sibling; and

2. Collect the following information from a person or facility specified in subsection (A), as applicable to a patient or the mother of a patient:

a. The name, address, and telephone number of the person or facility, or the identification number assigned by the Department to the person or facility;
   b. The date of first contact and the date of last contact;
   c. The date the patient was admitted to a hospital;
   d. The date the patient was admitted for:
      i. The birth of the patient, or
      ii. Treatment related to a possible birth defect in the patient;
   e. The name and address of the hospital or other location in which the patient was born;
   f. The name and address of a hospital in which the patient or the mother of the patient was admitted for treatment related to a possible birth defect in the patient;
   g. The specific unit of a hospital that provided medical services to the patient or the patient’s mother;
   h. The medical record number of the patient or the patient’s mother;
iv. The estimated gestational age of the patient at the time of each test,

v. The estimated date of confinement of the patient’s mother at the time of each test,

vi. The name of the prenatal diagnostic facility that performed each test, and

vii. The names of the individuals who interpreted the test results;

c. Whether any other types of tests were performed on the patient or the patient’s mother that may enable the diagnosis of a birth defect and, if so:

i. The types of tests performed,

ii. The test dates,

iii. The test results,

iv. The age or estimated gestational age of the patient at the time of each test,

v. The estimated date of confinement of the patient’s mother at the time of each test,

vi. The names of the facilities that performed the tests, and

vii. The names of the individuals who interpreted the test results;

d. Whether any surgical procedures associated with a birth defect were performed on the patient or the patient’s mother and, if so:

i. The types of surgical procedures performed,

ii. The dates of the surgical procedures,

iii. The results of the surgical procedures,

iv. The age or estimated gestational age of the patient at the time of each test,

v. The estimated date of confinement of the patient’s mother at the time of each test,

vi. The names of the facilities at which the surgical procedures were performed, and

vii. The names of the individuals who performed the surgical procedures;

e. For each diagnosis made for the patient or the patient’s mother:

i. The diagnosis,

ii. Whether the diagnosis is a principal or secondary diagnosis,

iii. The facility at which the diagnosis was made,

iv. The date on which the diagnosis was made, and

v. The name of the individual who made the diagnosis;

f. The number of times the patient’s mother has been pregnant;

g. The number of times a pregnancy of the patient’s mother has lasted:

i. More than 37 weeks,

ii. Between 20 and 37 weeks, and

iii. Less than 20 weeks;

h. The number of children who were born as a result of the patient’s mother’s pregnancies, and whether the children were born alive or dead;

i. Whether the patient is from a singleton or multiple gestation, and, if from a multiple gestation, whether a co-twin of the patient:

i. Is identical or fraternal;

ii. Is alive, and, if not alive, the co-twin’s date of death; and

iii. Has:

(1) The same birth defect as the patient,

(2) A different birth defect from that of the patient, or

(3) No birth defect;

jj. If the patient is being adopted or living with a guardian rather than a parent;

kk. If the patient is being adopted, the name, address, and telephone number of the individual who will adopt the patient;

ll. The date of last contact; and

mm. If the patient has died:

i. The patient’s date and county of death,

ii. The facility in which the patient’s death occurred, and

iii. Whether an autopsy was performed on the patient.

Historical Note


R9-4-504. Data Quality Assurance and Follow-up

A. The Department may require a hospital, clinic, high-risk perinatal practice, genetic testing facility, or prenatal diagnostic facility to revise a report:

1. That was submitted to the Department by the designee of the hospital, clinic, high-risk perinatal practice, genetic testing facility, or prenatal diagnostic facility under R9-4-502;

2. That was not prepared according to R9-4-502; and

3. By identifying the revisions that are needed in the report.

B. If a person receives a request from the Department for revision of a report under subsection (A), the person shall return a revised report, containing the revisions requested by the Department, to the Department within 15 business days after the date of the Department’s request, or by a date agreed to by the person and the Department.

C. The Department may discuss the information submitted to the Department as specified in R9-4-502 or collected as specified in R9-4-503(B)(2) with:

1. Any of the entities specified in R9-4-503(A) to obtain additional information about a patient’s diagnosis or treatment;

2. The Arizona Early Intervention Program, according to A.R.S. § 36-133(E); and

3. The parent or guardian of a patient, as allowed by A.R.S. § 36-133(E).

Historical Note


ARTICLE 6. OPIOID POISONING-RELATED REPORTING

R9-4-601. Definitions

In this Article, unless otherwise specified:

1. “Administrator” means the individual who is a senior leader in a health care institution or correctional facility.

2. “Ambulance service” has the same meaning as in A.R.S. § 36-2201.

3. “Business day” means the period from 8:00 a.m. to 5:00 p.m. on a Monday, Tuesday, Wednesday, Thursday, or Friday that is not a state holiday.

4. “Clinical laboratory” has the same meaning as in A.R.S. § 36-451.

5. “Correctional facility” has the same meaning as in A.A.C. R9-6-101.

6. “Dispense” has the same meaning as in A.R.S. § 32-1901.
7. “Emergency medical services provider” has the same meaning as in A.R.S. § 36-2201.
8. “First response agency” means:
   a. An ambulance service,
   b. An emergency medical services provider, or
   c. A law enforcement agency.
9. “Health care institution” has the same meaning as in A.R.S. § 36-401.
10. “Law enforcement agency” has the same meaning as in A.A.C. R13-1-101.
11. “Medical examiner” has the same meaning as in A.R.S. § 36-301.
12. “Naloxone” means a specific opioid antagonist that has been used since 1971 to block the effects of an opioid in an individual.
13. “Neonatal abstinence syndrome” means a set of signs of opioid withdrawal occurring in an individual shortly after birth that are indicative of opioid exposure while in the womb.
15. “Opioid antagonist” means a prescription medication, as defined in A.R.S. § 32-1901, that:
   a. Is approved by the U.S. Department of Health and Human Services, Food and Drug Administration; and
   b. When administered, reverses, in whole or in part, the pharmacological effects of an opioid in the body.
16. “Opioid overdose” means respiratory depression, slowing heart rate, or unconsciousness or mental confusion caused by the administration, including self-administration, of an opioid to an individual.
17. “Pharmacist” has the same meaning as in A.R.S. § 36-2501.
18. “Pharmacological effects” has the same meaning as in A.R.S. § 32-1901.

Historical Note
New Section made by emergency rulemaking at 23 A.A.R. 2857, effective September 21, 2017, for 180 days (Supp. 17-3). Emergency expired; New Section amended by emergency rulemaking at 24 A.A.R. 630, effective March 20, 2018, for 180 days (Supp. 18-1). New permanent Section made by final rulemaking at 24 A.A.R. 783, with an immediate effective date of April 5, 2018 (Supp. 18-2).

R9-4-602. Opioid Poisoning-Related Reporting Requirements
A. A first response agency shall, either personally or through a representative, submit a report to the Department, in a Department-provided format and within five business days after an encounter with an individual with a suspected opioid overdose, that includes:
   1. The following information about the first response agency:
      a. Name;
      b. Street address, city, county, and zip code;
      c. Whether the first response agency reporting is:
         i. An ambulance service,
         ii. An emergency medical services provider, or
         iii. A law enforcement agency; and
      d. If applicable, the certificate number issued by the Department to the ambulance service;
   2. The name, title, telephone number, and email address of a point of contact for the first response agency required to report;
   3. The following information about the location at which the first response agency encountered the individual:
      a. Street address or, if the location at which the first response agency encountered the individual does not have a street address, another indicator of the location at which the encounter occurred;
      b. City, if applicable;
      c. County;
      d. State; and
      e. Zip code;
   4. If applicable, the date and time the first response agency was dispatched to the location specified according to subsection (A)(3);
   5. The following information, as known, about the individual with a suspected opioid overdose or who died of a suspected opioid overdose:
      a. Name,
      b. Date of birth,
      c. Age in years,
      d. Gender,
      e. Race and ethnicity, and
      f. Reason for suspecting that the individual had an opioid overdose;
   6. Whether naloxone or another opioid antagonist designated according to A.R.S. § 36-2228 was administered to the individual before the first response agency encountered the individual and, if so:
      a. The number of doses of naloxone or other opioid antagonist administered to the individual; and
      b. As applicable, that the naloxone or other opioid antagonist administered to the individual by:
         i. Another individual; or
         ii. Another first response agency and, if so the type of first response agency that administered the naloxone or other opioid antagonist to the individual;
   7. Whether naloxone or another opioid antagonist designated according to A.R.S. § 36-2228 was administered to the individual by the first response agency and, if so, the number of doses of naloxone or other opioid antagonist administered to the individual;
   8. Whether the disposition of the individual was that the individual:
      a. Survived the suspected opioid overdose; or
      b. Was pronounced dead:
         i. At the location specified according to subsection (A)(3), or
         ii. After leaving the location specified according to subsection (A)(3);
   9. If the individual was transported by a first response agency:
      a. The type of first response agency that transported the individual; and
      b. Whether the individual was transported to:
         i. A hospital and, if so, the name of the hospital to which the individual was transported;
         ii. Another class of health care institution and, if so, the name of the health care institution to which the individual was transported; or
         iii. A correctional facility and, if so, the name of the correctional facility to which the individual was transported; and
   10. The date of the report.
B. The following are not required to submit a report under this Article:
CHAPTER 4. DEPARTMENT OF HEALTH SERVICES - NONCOMMUNICABLE DISEASES

1. An administrator of a health care institution licensed under 9 A.A.C. 10, for an opioid overdose resulting from the administration of the opioid to a patient in the health care institution if the opioid overdose is addressed through the health care institution's quality management program; or

2. A pharmacist for naloxone or another opioid antagonist that is dispensed in connection with a surgical procedure, as defined in A.A.C. R9-10-101, or other invasive procedure performed in a health care institution.

C. Except as prohibited by Title 42 Code of Federal Regulations, Chapter I, Subchapter A, Part 2 or as specified in subsection (B), a health professional or the administrator of a health care institution licensed under 9 A.A.C. 10 shall, either personally or through a representative, submit a report to the Department, in a Department-provided format and within five business days after an encounter with an individual with a suspected opioid overdose, that includes:

1. The name, street address, city, county, zip code, and telephone number of the health professional or health care institution;

2. If different from the person in subsection (C)(1), the name, title, telephone number, and email address of the individual reporting on behalf of the person in subsection (C)(1);

3. The following information about the individual with a suspected opioid overdose:
   a. The individual’s name;
   b. The individual’s street address, city, county, state, and zip code;
   c. The individual’s date of birth;
   d. The individual’s gender;
   e. The individual’s race and ethnicity;
   f. Whether the individual is pregnant and, if so, the expected date of delivery;
   g. If applicable, the name of the individual’s guardian; and
   h. Whether naloxone or another opioid antagonist designated according to A.R.S. § 36-2228 was administered to the individual before the health professional or health care institution encountered the individual and, if so:
      i. The type of first response agency that administered the naloxone or other opioid antagonist to the individual, or
      ii. That the naloxone or other opioid antagonist was administered to the individual by another individual;

4. The following information about the diagnosis of opioid overdose:
   a. The reason for suspecting that the individual had an opioid overdose;
   b. The date of the suspected opioid overdose;
   c. The date of diagnosis; and
   d. If the diagnosis was confirmed through one or more tests performed by a clinical laboratory, for each test:
      i. The name, address, and telephone number of the clinical laboratory;
      ii. The date a specimen was collected from the individual;
      iii. The type of specimen collected;
      iv. The type of laboratory test performed; and
      v. The laboratory test result and date of the result;

5. The following information about the suspected opioid overdose:
   a. Whether the opioid overdose appeared to be intentional or unintentional;
   b. The location where the opioid overdose took place;
   c. Whether the individual was alone at the time of the opioid overdose;
   d. Whether the individual was transported to the health professional or health care institution by a first response agency and, if so, the type of first response agency that transported the individual;
   e. The specific opioid that appeared to be responsible for the opioid overdose; and
   f. If known, whether:
      i. The individual was prescribed an opioid within the 90 calendar days before the date of the suspected opioid overdose;
      ii. The individual had been referred to receive behavioral health services, as defined in A.R.S. § 36-401; or
      iii. The opioid overdose was the first time the individual had an opioid overdose and, if not, the number of previous opioid overdoses the individual was known to have had;

6. Whether the individual with the suspected opioid overdose:
   a. Survived the suspected opioid overdose and:
      i. Was admitted to the health care institution;
      ii. Was transferred to another health care institution and, if so, the name of the health care institution;
      iii. Was discharged to a law enforcement agency or correctional facility and, if so, the name of the law enforcement agency or correctional facility's name, address, city, county, state, and zip code;
      iv. Was discharged to home; or
      v. Left the health care institution against medical advice; or
   b. Died and, if so, the date of death; and

7. The date of the report.

D. Except as prohibited by Title 42 Code of Federal Regulations, Chapter I, Subchapter A, Part 2, a health professional or the administrator of a health care institution licensed under 9 A.A.C. 10 shall, either personally or through a representative, submit a report to the Department, in a Department-provided format and within five business days after an encounter with an individual with suspected neonatal abstinence syndrome, that includes:

1. The name, street address, city, county, zip code, and telephone number of the health professional or health care institution;

2. If different from the person in subsection (D)(1), the name, title, telephone number, and email address of the individual reporting on behalf of the person in subsection (D)(1);

3. The following information about the individual with suspected neonatal abstinence syndrome:
   a. The individual’s name;
   b. The individual’s date of birth;
   c. The individual’s gender;
   d. The individual’s race and ethnicity;
   e. The name of the individual’s mother; and
   f. If not the individual’s mother, the name of the individual’s guardian;

4. The following information about a diagnosis of neonatal abstinence syndrome:
   a. The reason for suspecting that the individual has neonatal abstinence syndrome;
CHAPTER 4. DEPARTMENT OF HEALTH SERVICES - NONCOMMUNICABLE DISEASES

b. The date of the onset of signs of neonatal abstinence syndrome;
c. The date of diagnosis;
d. If the diagnosis was confirmed through one or more tests performed by a clinical laboratory, for each test:
   i. The name, address, and telephone number of the clinical laboratory;
   ii. The date a specimen was collected from the individual;
   iii. The type of specimen collected;
   iv. The type of laboratory test performed; and
   v. The laboratory test result and date of the result; and

e. Whether any of the following supported a diagnosis of neonatal abstinence syndrome:
   i. A maternal history of opioid use,
   ii. A positive laboratory test for opioid use by the individual’s mother, or
   iii. A positive laboratory test for opioids in the individual;

5. If known, the following information about the suspected neonatal abstinence syndrome:
   a. The source of the opioid believed to have caused the neonatal abstinence syndrome; and
   b. If the source of the opioid used by the individual’s mother was not through a prescription order, as defined in A.R.S. § 32-1901, the specific opioid used by the individual’s mother; and

6. The date of the report.

E. A pharmacist who dispenses naloxone or another opioid antagonist to an individual according to A.R.S. § 32-1979 shall, either personally or through a representative, submit a report as required in A.R.S. § 32-1979 to document the dispensing.

F. A medical examiner shall, either personally or through a representative, submit a report to the Department, in a Department-provided format and within five business days after the completion of the death investigation required in A.R.S. § 11-594 on the human remains of a deceased individual with a suspected opioid overdose, that includes:
   1. The following information about the medical examiner:
      a. Name; and
      b. Street address, city, county, and zip code;
   2. The following information about the deceased individual with a suspected opioid overdose:
      a. The deceased individual’s name;
      b. The deceased individual’s date of birth;
      c. The deceased individual’s gender;
      d. The deceased individual’s race and ethnicity;
      e. Whether the deceased individual was pregnant and, if so, the expected date of delivery;
      f. If applicable, the name of the deceased individual’s guardian; and
      g. Whether naloxone or another opioid antagonist was administered to the deceased individual before the deceased individual’s death and, if known:
         i. The type of first response agency that administered the naloxone or other opioid antagonist to the deceased individual, or
      ii. That the naloxone or other opioid antagonist was administered to the deceased individual by another individual;

3. The following information about the diagnosis of opioid overdose:
   a. The reason for suspecting that the deceased individual had an opioid overdose;
   b. The date of the opioid overdose;
   c. The date of diagnosis; and
   d. If the diagnosis was confirmed by clinical laboratory tests:
      i. The name, address, and telephone number of the clinical laboratory;
      ii. The date a specimen was collected from the deceased individual;
      iii. The type of specimen collected;
      iv. The type of laboratory test performed; and
      v. The laboratory test result and date of the result; and

4. If applicable, a copy of the clinical laboratory test results;

5. If known, the following information about the suspected opioid overdose:
   a. Whether the opioid overdose appeared to be intentional or unintentional;
   b. The location where the opioid overdose took place;
   c. Whether the deceased individual was alone at the time of the opioid overdose;
   d. The specific opioid that appeared to be responsible for the opioid overdose;
   e. Whether the deceased individual was prescribed an opioid within the 90 calendar days before the date of the opioid overdose; and
   f. Whether the opioid overdose was the first time the deceased individual was known to have had an opioid overdose and, if not, the number of previous opioid overdoses the deceased individual had

6. Whether the deceased individual with the suspected opioid overdose:
   a. Died from the suspected opioid overdose and, if so, the date of death; or
   b. Died from another cause after experiencing a suspected opioid overdose and, if so, the date of death; and

7. The date of the report.

G. Information collected on individuals pursuant to this Article is confidential according to:
   1. A.R.S. § 36-133(F); and
   2. If applicable, A.R.S. §§ 36-2401 through 36-2403.

Historical Note

New Section made by emergency rulemaking at 23 A.A.R. 2857, effective September 21, 2017, for 180 days (Supp. 17-3). Emergency expired; new Section amended by emergency rulemaking at 24 A.A.R. 630, effective March 20, 2018, for 180 days (Supp. 18-1). New permanent Section made by final rulemaking at 24 A.A.R. 783, with an immediate effective date of April 5, 2018 (Supp. 18-2).